RioDerm-002 is under clinical development by Rion and currently in Phase I for Radiation Injury. According to GlobalData, Phase I drugs for Radiation Injury does not have sufficient historical data to ...

Anifrolumab is under clinical development by AstraZeneca and currently in Phase II for Vitiligo. According to GlobalData, Phase II drugs for Vitiligo have a 42% phase transition success rate (PTSR) ...

Rostaporfin is under clinical development by TuHURA Biosciences and currently in Phase III for Metastatic Breast Cancer.

ACTUS-101 is under clinical development by Asklepios BioPharmaceutical and currently in Phase II for Pompe Disease.

GPN Vaccines, formerly GPN Vaccines, is a clinical-stage company focused on creating vaccines that offer robust protection against bacterial pathogens. It develops vaccines to protect adults and ...

EXO-CD24 is under clinical development by Nano24med and currently in Phase II for Acute Respiratory Distress Syndrome.

HMBD-001 is under clinical development by Hummingbird Bioscience and currently in Phase I for Pancreatic Ductal Adenocarcinoma.

Amivantamab is under clinical development by Johnson & Johnson and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas.

Zastaprazan is under clinical development by Onconic Therapeutics and currently in Phase III for Gastric Ulcers.

Azacitidine is under clinical development by Bristol-Myers Squibb and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

Bexotegrast is under clinical development by Pliant Therapeutics and currently in Phase II for Liver Fibrosis.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...